A reduction in the mRNA level of inflammatory mediators (iNOS, IL-6, IFN-, and TNF-) and increased expression of HSP 70 and 90 and antioxidant proteins such as HO-1, NQO-1, glutathione reductase, glutathione peroxidase 2, and GST-pi were observed (Park et al., 2020)
This depth of human trial evidence provides greater confidence in safety characterization compared to peptides with primarily theoretical or animal-based safety data
Patterns become visible in logs that might be missed otherwise
However, these have a crucial advantage, as they allow the qualities of the selected active substance to be tested in detail
Gap BPC 157 therapy was associated with a reduction in the musculoskeletal defect that had already occurred in the early stages, from the first post-operative day (Figure 7, Figure 8, Figure 9, Figure 10, Figure 11 and Figure 12)